Targeting OX40 With GBR 830, An OX40 Antagonist, Inhibits T Cell-Mediated Pathological Responses. J of Skin [Internet]. 2018 Dec. 17 [cited 2025 Oct. 6];2:S62. Available from: https://skin.dermsquared.com/skin/article/view/458